{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:54:55Z","timestamp":1791244495918,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Consun Pharmaceutical (Inner Mongolia) Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Uncoupling of the nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) axis and impaired cGMP synthesis are hallmarks of chronic kidney disease (CKD). While sGC has been a target of therapeutic interest for CKD, clinical progress has been limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this single center, phase 1 study (NCT07021157), the pharmacokinetics (PK), pharmacodynamics (PD), and safety of SK-08, a novel, oral sGC activator, were evaluated. Healthy participants were randomized to SK-08 or placebo in the single-ascending-dose phase; in the food-effect phase, SK-08 10\u00a0mg was administered under fasted and fed conditions. cGMP was the key PD biomarker, and exposure-response analyses were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Between 18th March 2025\u201317th June 2025, 16 participants were randomized and received SK-08 5\u00a0mg (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20093), 7.5\u00a0mg (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20093), or 10\u00a0mg (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20096), or placebo (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20094). Adverse events (AEs) were mild\/moderate and resolved spontaneously, those with an incidence\u2009&gt;\u200910% were hypotension (4\/12, 33.3%) and dizziness (2\/12, 16.7%). A higher C\n                      <jats:sub>max<\/jats:sub>\n                      was associated with an increased incidence of adverse drug reactions (ADRs) across all SK-08 doses. Under fasted conditions, the absorption and time to peak plasma concentration of SK-08 was fairly rapid (median T\n                      <jats:sub>max<\/jats:sub>\n                      2.5\u20135.0\u00a0h). Administration after a high-fat meal prolonged the median T\n                      <jats:sub>max<\/jats:sub>\n                      by 0.7\u00a0h; C\n                      <jats:sub>max<\/jats:sub>\n                      and AUC were decreased by ~\u200910%. Mean cGMP maximum percentage change (E\n                      <jats:sub>max<\/jats:sub>\n                      ) increased dose dependently, from 5.99% at 5\u00a0mg to 27.19% at 10\u00a0mg, with a median time to E\n                      <jats:sub>max of<\/jats:sub>\n                      2.75\u20136.00\u00a0h.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      SK-08 was well tolerated in healthy participants and induced dose-related sGC activation. A potential association between C\n                      <jats:sub>max<\/jats:sub>\n                      levels and the incidence of ADRs, and no clinically meaningful impact of food, was observed. These findings guide the optimization of a controlled-release formulation to maximize the therapeutic potential of SK-08.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Chinadrugtrials.org.cn (CTR20250337). Registered 20,250,126 Clinicaltrials.gov (NCT07021157). Registered 20,250,512.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-026-05138-y","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:54:15Z","timestamp":1783608855000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety, pharmacokinetic, and pharmacodynamic characteristics of SK-08, a soluble guanylate cyclase activator, after oral administration in healthy participants: a randomized phase 1 trial"],"prefix":"10.1186","volume":"27","author":[{"given":"Jian","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanghuan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caixia","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijing","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liya","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danna","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"issue":"10225","key":"5138_CR1","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/S0140-6736(19)32977-0","volume":"395","author":"P Cockwell","year":"2020","unstructured":"Cockwell P, Fisher L-A. The global burden of chronic kidney disease. Lancet. 2020;395(10225):662\u20134.","journal-title":"Lancet"},{"issue":"1","key":"5138_CR2","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1186\/s12889-025-21851-z","volume":"25","author":"L Deng","year":"2025","unstructured":"Deng L, Guo S, Liu Y, Zhou Y, Liu Y, Zheng X, Yu X, Shuai P. Global, regional, and national burden of chronic kidney disease and its underlying etiologies from 1990 to 2021: a systematic analysis for the Global Burden of Disease Study 2021. BMC Public Health. 2025;25(1):636.","journal-title":"BMC Public Health"},{"key":"5138_CR3","doi-asserted-by":"crossref","unstructured":"Liyanage T, Toyama T, Hockham C, Ninomiya T, Perkovic V, Woodward M, Fukagawa M, Matsushita K, Praditpornsilpa K, Hooi LS, et al. Prevalence of chronic kidney disease in Asia: a systematic review and analysis. BMJ Glob Health 2022;7(1).","DOI":"10.1136\/bmjgh-2021-007525"},{"issue":"11","key":"5138_CR4","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1093\/cvr\/cvad083","volume":"119","author":"C Zoccali","year":"2023","unstructured":"Zoccali C, Mallamaci F, Adamczak M, de Oliveira RB, Massy ZA, Sarafidis P, Agarwal R, Mark PB, Kotanko P, Ferro CJ, et al. Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association. Cardiovasc Res. 2023;119(11):2017\u201332.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"5138_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s12325-021-01927-z","volume":"39","author":"M Evans","year":"2022","unstructured":"Evans M, Lewis RD, Morgan AR, Whyte MB, Hanif W, Bain SC, Davies S, Dashora U, Yousef Z, Patel DC, et al. A Narrative Review of Chronic Kidney Disease in Clinical Practice: Current Challenges and Future Perspectives. Adv Ther. 2022;39(1):33\u201343.","journal-title":"Adv Ther"},{"key":"5138_CR6","doi-asserted-by":"crossref","unstructured":"KDIGO 2024 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2024;105(4s):S117-s314.","DOI":"10.1016\/j.kint.2023.10.018"},{"issue":"Supplement1","key":"5138_CR7","doi-asserted-by":"publisher","first-page":"i47","DOI":"10.1093\/ndt\/gfae216","volume":"40","author":"M Nardone","year":"2025","unstructured":"Nardone M, Yau K, Kugathasan L, Odutayo A, Mohsen M, Ouimet JP, Sridhar VS, Cherney DZI. Upcoming drug targets for kidney protective effects in chronic kidney disease. Nephrol Dial Transpl. 2025;40(Supplement1):i47\u201358.","journal-title":"Nephrol Dial Transpl"},{"issue":"1","key":"5138_CR8","doi-asserted-by":"publisher","first-page":"e0261000","DOI":"10.1371\/journal.pone.0261000","volume":"17","author":"L Hu","year":"2022","unstructured":"Hu L, Chen Y, Zhou X, Hoek M, Cox J, Lin K, Liu Y, Blumenschein W, Grein J, Swaminath G. Effects of soluble guanylate cyclase stimulator on renal function in ZSF-1 model of diabetic nephropathy. PLoS ONE. 2022;17(1):e0261000.","journal-title":"PLoS ONE"},{"issue":"1","key":"5138_CR9","doi-asserted-by":"publisher","first-page":"F148","DOI":"10.1152\/ajprenal.00247.2019","volume":"318","author":"CM Shea","year":"2020","unstructured":"Shea CM, Price GM, Liu G, Sarno R, Buys ES, Currie MG, Masferrer JL. Soluble guanylate cyclase stimulator praliciguat attenuates inflammation, fibrosis, and end-organ damage in the Dahl model of cardiorenal failure. Am J Physiol Ren Physiol. 2020;318(1):F148\u201359.","journal-title":"Am J Physiol Ren Physiol"},{"issue":"11","key":"5138_CR10","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1111\/bph.15586","volume":"179","author":"D Stehle","year":"2022","unstructured":"Stehle D, Xu MZ, Schomber T, Hahn MG, Schweda F, Feil S, Kraehling JR, Eitner F, Patzak A, Sandner P, et al. Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney. Br J Pharmacol. 2022;179(11):2476\u201389.","journal-title":"Br J Pharmacol"},{"key":"5138_CR11","doi-asserted-by":"crossref","unstructured":"Kraehling JR, Benardeau A, Schomber T, Popp L, Vienenkoetter J, Ellinger-Ziegelbauer H, Pavkovic M, Hartmann E, Siudak K, Freyberger A, et al. The sGC activator runcaciguat has kidney protective effects and prevents a decline of kidney function in ZSF1 rats. Int J Mol Sci 2023;24(17).","DOI":"10.3390\/ijms241713226"},{"issue":"6","key":"5138_CR12","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1093\/ndt\/gfae261","volume":"40","author":"RT Gansevoort","year":"2025","unstructured":"Gansevoort RT, Wheeler DC, Deb\u00e9n FM, Speeckaert M, Thomas D, Berger M, Klein S, Friedrichs F, Paraschin K, Schmieder RE. The soluble guanylate cyclase activator runcaciguat significantly improves albuminuria in patients with chronic kidney disease: a randomized placebo-controlled clinical trial. Nephrol Dial Transpl. 2025;40(6):1147\u201360.","journal-title":"Nephrol Dial Transpl"},{"key":"5138_CR13","unstructured":"Technical guidelines for the correlation evaluation of adverse events in drug clinical trials. (Trial)"},{"issue":"6","key":"5138_CR14","doi-asserted-by":"publisher","first-page":"526","DOI":"10.2174\/138920010791636185","volume":"11","author":"Y Sheng","year":"2010","unstructured":"Sheng Y, He Y, Huang X, Yang J, Wang K, Zheng Q. Systematic evaluation of dose proportionality studies in clinical pharmacokinetics. Curr Drug Metab. 2010;11(6):526\u201337.","journal-title":"Curr Drug Metab"},{"issue":"1","key":"5138_CR15","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/pst.326","volume":"8","author":"J Hummel","year":"2009","unstructured":"Hummel J, McKendrick S, Brindley C, French R. Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion. Pharm Stat. 2009;8(1):38\u201349.","journal-title":"Pharm Stat"},{"issue":"21","key":"5138_CR16","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1001\/jama.2015.15734","volume":"314","author":"M Gheorghiade","year":"2015","unstructured":"Gheorghiade M, Greene SJ, Butler J, Filippatos G, Lam CSP, Maggioni AP, Ponikowski P, Shah SJ, Solomon SD, Kraigher-Krainer E, et al. Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. JAMA. 2015;314(21):2251\u201362.","journal-title":"JAMA"},{"issue":"4","key":"5138_CR17","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s00228-020-03023-7","volume":"77","author":"M Boettcher","year":"2021","unstructured":"Boettcher M, Thomas D, Mueck W, Loewen S, Arens E, Yoshikawa K, Becker C. Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects. Eur J Clin Pharmacol. 2021;77(4):527\u201337.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"5138_CR18","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s40262-015-0337-4","volume":"55","author":"X Zhao","year":"2016","unstructured":"Zhao X, Wang Z, Wang Y, Zhang H, Blode H, Yoshikawa K, Becker C, Unger S, Frey R, Cui Y. Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator Riociguat in Healthy Young Chinese Male Non-Smokers and Smokers: Results of a Randomized, Double-Blind, Placebo-Controlled Study. Clin Pharmacokinet. 2016;55(5):615\u201324.","journal-title":"Clin Pharmacokinet"},{"key":"5138_CR19","doi-asserted-by":"publisher","first-page":"1359939","DOI":"10.3389\/fphar.2024.1359939","volume":"15","author":"YZ Gui","year":"2024","unstructured":"Gui YZ, Wang W, Wu QQ, Ding QC, Qian HJ, Lu QB, Zhang YJ, Zhuang YL, Deng L, Zuo YL, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of a soluble guanylate cyclase stimulator, HEC95468, in healthy volunteers: a randomized, double-blinded, placebo-controlled phase 1 trial. Front Pharmacol. 2024;15:1359939.","journal-title":"Front Pharmacol"},{"issue":"8","key":"5138_CR20","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1177\/0091270008319793","volume":"48","author":"R Frey","year":"2008","unstructured":"Frey R, M\u00fcck W, Unger S, Artmeier-Brandt U, Weimann G, Wensing G. Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers. J Clin Pharmacol. 2008;48(8):926\u201334.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"5138_CR21","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/cpdd.627","volume":"8","author":"JP Hanrahan","year":"2019","unstructured":"Hanrahan JP, Wakefield JD, Wilson PJ, Mihova M, Chickering JG, Ruff D, Hall M, Milne GT, Currie MG, Profy AT. A Randomized, Placebo-Controlled, Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Soluble Guanylate Cyclase Stimulator Praliciguat in Healthy Subjects. Clin Pharmacol Drug Dev. 2019;8(5):564\u201375.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"7","key":"5138_CR22","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1111\/bcp.14676","volume":"87","author":"JR Klinger","year":"2021","unstructured":"Klinger JR, Chakinala MM, Langleben D, Rosenkranz S, Sitbon O. Riociguat: Clinical research and evolving role in therapy. Br J Clin Pharmacol. 2021;87(7):2645\u201362.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"5138_CR23","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s40265-021-01496-z","volume":"81","author":"A Markham","year":"2021","unstructured":"Markham A, Duggan S. Vericiguat: First Approval. Drugs. 2021;81(6):721\u20136.","journal-title":"Drugs"},{"issue":"9","key":"5138_CR24","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1681\/ASN.0000000000000418","volume":"35","author":"HJL Heerspink","year":"2024","unstructured":"Heerspink HJL, Cherney D, Gafor AHA, G\u00f3rriz JL, Pergola PE, Tang SCW, Desch M, Iliev H, Sun Z, Steubl D, et al. Effect of Avenciguat on Albuminuria in Patients with CKD: Two Randomized Placebo-Controlled Trials. J Am Soc Nephrol. 2024;35(9):1227\u201339.","journal-title":"J Am Soc Nephrol"},{"key":"5138_CR25","doi-asserted-by":"crossref","unstructured":"Krishnan SM, Kraehling JR, Eitner F, B\u00e9nardeau A, Sandner P. The impact of the nitric oxide (NO)\/soluble guanylyl cyclase (sGC) signaling cascade on kidney health and disease: a preclinical perspective. Int J Mol Sci 2018;19(6).","DOI":"10.3390\/ijms19061712"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-05138-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05138-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05138-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:08:51Z","timestamp":1791241731000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-05138-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5138"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-05138-y","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"13 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The protocol and all relevant documents were approved by the Clinical Trials Ethics Committee of the First Affiliated Hospital, College of Medicine, Zhejiang University. The trial was conducted in accordance with the Chinese Guidelines for Good Clinical Practice, applicable local laws and regulations, and the principles outlined in the Declaration of Helsinki and its subsequent revisions. All participants provided written, informed consent before participation.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patients and public were not involved in the in the design, conduct and reporting of the trial.","order":3,"name":"Ethics","label":"Patient and public involvement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This product has a patent sharing collaboration with WuXi AppTec Co., Ltd. Ying Du, Hong Zhou, Hanghuan Jia, Yingying Song, Danna Jiang, and Jing Yang are all employees at Consun Pharmaceutical (Inner Mongolia) Co., Ltd. All other authors have no other conflicts of interest to declare.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"586"}}